![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Polyradiculoneuropathy - 50 Studies Found
Completed |
: Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy : Polyradiculoneuropathy, Chronic Inflammatory Demyelinating : 1999-10-18 : Drug: immune globulin |
Completed |
: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) :
|
Recruiting |
: Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2015-09-11 :
|
Not yet recruiting |
: Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2016-08-29 :
|
Recruiting |
: Subcutaneous Immunoglobulin for CIDP : Chronic Inflammatory Demyelinating Polyneuropathy : 2014-12-12 : Drug: Immune Globulin Subcutaneous (Human) Patients who have CIDP and are on IVIG will be allowed in the |
Completed |
: MRI in Diagnosing and Monitoring CIDP : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2013-12-06 |
Recruiting |
: IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements : Chronic Inflammatory Demyelinating Polyneuropathy : 2015-03-13 : Drug: Intravenous Immunoglobulin The decision to treat with IVIg will be entirely at the discretion of t |
Recruiting |
: Efficacy and Safety Study of I10E in Treatment of Patients With CIDP : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2014-11-13 : Drug: I10E Patients who meet all eligibility criteria will |
Recruiting |
: Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2014-12-11 : Drug: I10E Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 4 |
Recruiting |
: Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2016-11-02 : Biological: HYQVIA Other Names:
|